A Phase 3 interventional study of Acoramidis (AG10) in Amyloid Cardiomyopathy, Transthyretin-Related, sponsored by Eidos Therapeutics, a BridgeBio company. Active, not recruiting at 72 sites in 17 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Eidos Therapeutics, a BridgeBio company · Phase 3, Interventional, and Treatment
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
The primary objective of this prospective, multi-center, open-label study is to evaluate the long-term safety and tolerability of acoramidis in patients with an established diagnosis of ATTR-CM and heart failure who are concomitantly treated with currently recommended heart failure therapies. Secondary efficacy and PD objectives will be assessed. Exploratory objectives may also be assessed.
All participants who complete 30 months of blinded study treatment and the Month 30 assessments of the double-blind treatment period of the Phase 3 ATTRibute-CM trial (AG10-301) may be eligible to participate in this Open Label Extension (OLE) study of acoramidis. The Day 1 visit in Study AG10-304 may be the same as the Month 30 visit in Study AG10-301. Under these circumstances, the last dose of Investigational Medicinal Product (IMP) in Study AG10-301 (either blinded acoramidis or matching placebo) will be the night before the day of the Month 30 visit. The first dose of open-label acoramidis in Study AG10-304 will be during the Study AG10-304 Day 1 visit after baseline assessments have been completed.
Currently, tafamidis is approved for the treatment of ATTR-CM in some regions. Participants are not allowed to be treated with tafamidis or any other ATTR-CM-specific approved or investigational treatment, or therapies used off-label or as non-prescription supplements for ATTR-CM at any time during the study. If participants choose treatment with an alternative treatment as described above, they will be asked to discontinue acoramidis and complete an End of Treatment (EoT) form, and they may be asked to discontinue/withdraw from the study. If a participant discontinues/withdraws from the study, the participant will be asked to complete an early termination visit and a safety follow-up visit.
Participants are not permitted to participate in another interventional clinical trial (except Study AG10-301) within 30 days prior to dosing and throughout Study AG10-304. Participants who choose to participate in another interventional clinical trial will be asked to withdraw from acoramidis and complete an EoT form, and they may be asked to discontinue/withdraw from the study. If a participant discontinues/withdraws from the study, the participant will be asked to complete an early termination visit and a safety follow-up visit. Participation in observational and/or registry studies should be discussed with the Medical Monitor.
Exclusion Criteria:
Open-label study all participants will receive AG10 during this study.
Drug: Acoramidis (AG10)
Acoramidis (AG10) twice daily
Also known as: AG10, ALXN 2060
Incidence of treatment-emergent Adverse Events [Safety and Tolerability]
Incidence of each treatment-emergent adverse events measured over 60 Months or study completion
Time frame: 60 months
Evaluate all-cause mortality and cardiovascular mortality
Assessment of All-cause mortality and CV mortality during study period
Time frame: 60 months
Evaluate the effect of acoramidis on the 6-minute walk test (6MWT)
Change from Baseline in distance walked during the 6MWT during study period
Time frame: 60 months
Evaluate the effect of acoramidis on health-related quality of life Kansas City Cardiomyopathy Questionnaire
Change from Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score during study period \[scale is scored from 0-100, where 0=Poor, 100=Excellent\]
Time frame: 60 months
Evaluate the effect of acoramidis on the frequency of CV-related hospitalization
assess CV-related hospitalization during the study period
Time frame: 60 months
Plan to share: Undecided
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial→
Eidos Therapeutics, a BridgeBio company